Difference between revisions of "Busulfan (Myleran)"
Jump to navigation
Jump to search
m (Text replacement - "http://chemocare.com/chemotherapy" to "https://chemocare.com/chemotherapy") |
m |
||
| Line 11: | Line 11: | ||
*[[Chronic lymphocytic leukemia]] | *[[Chronic lymphocytic leukemia]] | ||
*[[Chronic myelogenous leukemia]] | *[[Chronic myelogenous leukemia]] | ||
| − | |||
*[[Ewing sarcoma]] | *[[Ewing sarcoma]] | ||
| + | *Non-Hodgkin lymphoma | ||
| + | **[[Anaplastic large cell lymphoma]] | ||
| + | **[[CNS lymphoma]] | ||
| + | **[[Diffuse large B-cell lymphoma]] | ||
| + | **[[Mantle cell lymphoma]] | ||
| + | **[[NK- and T-cell lymphoma]] | ||
| + | **[[Peripheral T-cell lymphoma]] | ||
| + | **[[Primary mediastinal B-cell lymphoma]] | ||
| + | *[[Myelodysplastic syndrome]] | ||
| + | *[[Neuroblastoma]] | ||
==Diseases for which it was used== | ==Diseases for which it was used== | ||
| Line 40: | Line 49: | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:Acute promyelocytic leukemia medications]] | [[Category:Acute promyelocytic leukemia medications]] | ||
| + | [[Category:Anaplastic large cell lymphoma medications]] | ||
[[Category:Chronic lymphocytic leukemia medications]] | [[Category:Chronic lymphocytic leukemia medications]] | ||
[[Category:Chronic myelogenous leukemia medications]] | [[Category:Chronic myelogenous leukemia medications]] | ||
[[Category:CNS lymphoma medications]] | [[Category:CNS lymphoma medications]] | ||
| + | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:Ewing sarcoma medications]] | [[Category:Ewing sarcoma medications]] | ||
| − | [[Category:Multiple myeloma medications]] | + | [[Category:Mantle cell lymphoma medications]] |
| + | [[Category:Myelodysplastic syndrome medications]] | ||
| + | [[Category:Neuroblastoma medications]] | ||
| + | [[Category:NK- and T-cell lymphoma medications]] | ||
| + | [[Category:Peripheral T-cell lymphoma medications]] | ||
| + | [[Category:Primary mediastinal B-cell lymphoma medications]] | ||
| + | [[Category:Multiple myeloma medications (historic)]] | ||
[[Category:FDA approved in 1954]] | [[Category:FDA approved in 1954]] | ||
Revision as of 18:45, 25 April 2022
General information
Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.[1][2][3][4]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Chronic lymphocytic leukemia
- Chronic myelogenous leukemia
- Ewing sarcoma
- Non-Hodgkin lymphoma
- Myelodysplastic syndrome
- Neuroblastoma
Diseases for which it was used
Patient drug information
- Busulfan (Myleran) package insert[1]
- Busulfan (Myleran) patient drug information (Chemocare)[5]
- Busulfan (Myleran) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 6/26/1954: Initial FDA approval
- 1/23/2003: (earliest label available at Drugs@FDA) indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia.
Also known as
- Brand names: Busulfex, Myleran
References
- ↑ 1.0 1.1 1.2 Busulfan (Myleran) package insert
- ↑ Busulfan (Myleran) package insert (locally hosted backup)
- ↑ Busulfan (Busulfex) package insert
- ↑ Busulfan (Busulfex) package insert (locally hosted backup)
- ↑ Busulfan (Myleran) patient drug information (Chemocare)
- ↑ Busulfan (Myleran) patient drug information (UpToDate)
Categories:
- Drugs
- Oral medications
- Intravenous medications
- Alkylating agents
- Irritant
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Anaplastic large cell lymphoma medications
- Chronic lymphocytic leukemia medications
- Chronic myelogenous leukemia medications
- CNS lymphoma medications
- Diffuse large B-cell lymphoma medications
- Ewing sarcoma medications
- Mantle cell lymphoma medications
- Myelodysplastic syndrome medications
- Neuroblastoma medications
- NK- and T-cell lymphoma medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- Multiple myeloma medications (historic)
- FDA approved in 1954